InvestSMART

Vitrafy Life Sciences Limited (ASX:VFY)

ALERT: Price-sensitive ASX Announcement for VFY
Current share price for VFY : $3.500 0.41 (13.27%)+
Announcement
Release
29 Jul 2026 8:29AM
Price at Release
$3.090
Full Release
download
Summary
Vitrafy Life Sciences Limited reported significant progress in Q4 FY26, including a $32 million capital raise, resulting in $41.2 million in cash and term deposits. The company achieved a 94.4% post-thaw platelet recovery in USAISR Phase II testing, secured partnerships with U.S. blood networks, and expanded its U.S. team. The annual aquaculture cryopreservation season saw a 68% increase in throughput. Despite a net operating cash outflow of $4.7 million, Vitrafy maintains funding for approximately 8.7 quarters. Development of Guardion units and progress towards medical device registration continued, demonstrating significant momentum in both financial and operational areas.
Key Points
  • Vitrafy Life Sciences Limited completed a $32 million capital raise in Q4 FY26.
  • The company reported $41.2 million in cash and term deposits as of June 2026.
  • Successful completion of USAISR Phase II in-vitro platelets testing with 94.4% post-thaw recovery.
  • Partnerships secured with U.S. blood collection networks, Vitalant and Hoxworth.
  • Annual cryopreservation season for aquaculture increased throughput by ~68%.
  • Net operating cash outflow for the quarter was $4.7 million.
  • The company has approximately 8.7 quarters of funding available based on current cash usage.
  • Development of Guardion units and progress towards medical device registration continued.
  • U.S. operations expanded with key senior appointments in science and sales.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.